

Index

- abdominal pain, 340
 adnexal torsion, 344–6
 appendicitis, 340–2
 constipation, 343–4
 intestinal malrotation with volvulus, 343
 intussusception, 342–3
 Meckel's diverticulum, 344
 mittelschmerz, 344
see also pelvic pain
- abnormal vaginal bleeding, 1, 8
 adolescent, 204, 210–13
 examination, 211
 history, 210–11
 laboratory evaluation, 211–12
 management, 212–13
- child, 81–6
 causes, 81, 82–6
 endocrine bleeding, 85–6
 foreign bodies, 83
 prolapsed urethra, 83–4
 severe vaginal infections, 82–3
 vulvar lesions, 83
 xanthogranuloma of the vagina, 85
- psychologic aspects, 132
see also anovulatory dysfunctional uterine bleeding (ADUB)
- abortion, 303–5
 consent issues, 455
 incomplete, 353
 spontaneous, 353
 threatened, 353
- abscess
 labium majus, 60–2
 renal, 436
 tubo-ovarian (TOA), 353, 354, 355, 434–5
- acetaminophen, 195
- aciclovir (acyclovir), 409–10
- acrodermatitis enteropathica (AE), 372
- acupuncture, chronic pelvic pain, 199
- acute ovarian failure (AOF), 445
- acute pelvic pain, 347–57, 433–4
 causes, 348
 early pregnancy complications, 348–53
 ovarian torsion, 356–7
 pelvic inflammatory disease, 353–6
see also pelvic pain
- adenocarcinoma, cervical, 459
- adipose tissue, 327
- adnexal masses, 248–51
- adnexal torsion, 250–1, 344, 356–7, 385–6, 433–4
 idiopathic, 344–6
- adolescents, 56–8, 299
 adolescent-friendly services, 134
 birth rates, 265–7
see also contraception
- coitarche, 129–30
 confidentiality, 129
 contraception, 138
 developmental stages, 134–5
 emancipation, 129
 examination, 58, 127
 first gynecologic examination, 127–8, 136–7
- first gynecologic encounter, 126–8
 parental involvement, 126–7
- history taking, 57–8, 135–6
 medical history, 126
 sexual history, 126, 136
- labor in, 311–14
 masturbation, 128
 obstetric management, 314–15
 pregnancy, 138–9
 preliminary preparation, 56–7
- sexuality, 124–30, 485
 mass media role, 300
 physiology of, 125
 sexually transmitted infections, 129, 137–8
- adrenarche, 160
 premature, 162
- adrenocortical neoplasms, 442–3
- agglutination, labia minora, 6, 240–2, 364
- allantois abnormalities, 430
- 5 α -reductase (5 α -RD2) deficiency, 21
- amastia, 258
- amazia, 258
- ambiguous genitalia, 21
see also disorders of sex development (DSD)
- amenorrhea, 150–7
 etiologies, 150–4
 hypothalamus/hypogonadotropic hypogonadism, 152–3
 outflow tract anomalies, 151
 ovary/peripheral/hypergonadotropic hypogonadism, 151–2
 pituitary, 152
- evaluation, 154–6
 diagnostic medications, 156
 examination, 155
- family history, 154–5
 history, 154
 imaging, 155–6
 laboratory evaluation, 155
 treatment, 156–7
 in PCOS, 332
- analgesics, chronic pelvic pain, 195–6
- anastrozole, endometriosis, 185
- androgen insensitivity (AIS), 13, 42–3
 amenorrhea and, 151
 history, 42–3
 long-range follow-up, 50
see also complete androgen insensitivity syndrome (CAIS); partial androgen insensitivity syndrome (PAIS)
- androgen receptor (AR), 43
- androgen secretion, 43
 abnormal secretion and anovulation, 320–1
 androgen insensitivity syndrome, 45
- androgen synthesis regulation, 324
- androgenization *see* hyperandrogenism
- anesthesia, 247–8
- anovulation, 462–3
 PCOS, 318, 320–3
 abnormal androgen production, 320–1
 management, 331, 332
 role of hyperinsulinemia and obesity, 321
 synergism between hyperinsulinemia and hyperandrogenemia, 323
- anovulatory dysfunctional uterine bleeding (ADUB), 8, 132, 204–9
 evaluation, 205–6, 208
 hospitalization, 207–9
 management, 208–9
 office management, 206–7
 pathophysiology, 204–5
see also abnormal vaginal bleeding
- antibiotics, pelvic inflammatory disease, 355
- anticonvulsants, chronic pelvic pain, 198
- antidepressants, chronic pelvic pain, 198
- aphallia, 22
- aphthous ulceration, 360–1
- appendicitis, 340–2, 435
- aromatase, 185
- aromatase inhibitors (AIs)
 chronic pelvic pain, 197
 endometriosis, 185
- athelia, 258
- atopic dermatitis (AD), 6, 67–72

- atypical-appearing genitalia, 14
see also disorders of sex development (DSD)
- bacterial vaginosis (BV), 418
- Behçet disease, 77–8, 360–1, 373–4
- benign cystic teratoma, 381, 386–7
- benign familial pemphigus, 374
- bilateral adrenalectomy, 33
- bladder trauma, 103
- bleeding disorders, 84, 210, 211, 212
see also abnormal vaginal bleeding
- bone changes, immature mammals, 308–9
- borderline ovarian tumors, 394–5, 446, 468
- breast
 asymmetry, 259
 atrophy, 258
 bloody nipple discharge, neonates and infants, 257
 breast cancer risks, 263
 oral contraceptives, 263
 congenital anomalies, 258
 development, 141, 143, 256, 257
 premature thelarche, 6–7, 161–2, 257–8
 developmental anomalies, 258–9
 examination, 127
 galactorrhea in newborns, 256–7
 hypertrophy, 258–9
 masses, 259–62
 adolescents, 260–1
 children, 259–60
 evaluation, 261–2
 mastitis, 259
 persistent nodules in the neonate, 256
 screening, 263
- bullous impetigo, 375
- burns, genital, 103–4
- cancer, childhood, 445
see also specific types of cancer
- candida infections, 419
 vaginitis, 65–6
 vulva, 358
- carcinoma
 breast, 261
 risks, 263
 embryonal, 471
 endometrial, 465
 ovarian, 382
see also cervical cancer
- cardiac abnormalities, Turner syndrome, 38
- cellulitis, perineal streptococcal, 375–6
- central precocious puberty (CPP), 153, 165
 therapy, 166–8
see also puberty
- cervical cancer, 400–1, 446, 457–61
 adenocarcinoma, 459
 HPV and, 457–61
 prophylactic vaccine, 403–6
 precancerous changes, 457–9
 screening *see* cervical cytology
- cervical cap, 291
- cervical cytology, 401–6, 458
- abnormal cytology management, 402–3
 atypical glandular cells, 403
 atypical squamous cells of undetermined significance (ASCUS), 402
 high-grade squamous intraepithelial lesions, 403
 low-grade squamous intraepithelial lesions, 402–3
 classification, 401–2, 458–9
 screening guidelines, 401–2
- cervical dysplasia, 400–1
 cervical intraepithelial neoplasia 1, 403
 cervical intraepithelial neoplasia 2/3, 403
 treatment, 403
see also cervical cytology
- cervicitis, sexually transmitted infections and, 419–20
- chancer, 421
- chancroid, 421
- chemotherapy
 amenorrhea and, 152
 germ cell tumors, 392–3
 ovarian function and, 445
see also fertility preservation
- rhabdomyosarcoma, 395
- child, 53–6
 assessment and plan, 56
 examination, 55–6
 history taking, 55
 preliminary preparations, 53–4
 prepubertal, 9–10
 young, 9
- child protection issues, 449–52
see also sexual abuse
- Chlamydia trachomatis*, 353–5, 419–20
 screening, 424
- choriocarcinoma, 392, 477–8
- chronic bullous disease of childhood (CBDC), 373
- chronic pelvic pain (CPP), 174–7, 194
 definition, 174
 differential diagnosis, 175
 interstitial cystitis (IC), 199–200
 irritable bowel syndrome (IBS), 200
 laparoscopy role, 175–7, 251–2
 management, 194–201
 acupuncture, 199
 anticonvulsants, 198
 antidepressants, 198
 associated conditions, 199–200
 expectations, 201
 hormonal management, 196–7
 multidisciplinary model, 194–5
 narcotic analgesics, 196
 nonnarcotic analgesics, 195–6
 physical therapy, 199
 psychosocial management, 198–9
 role of parents, 201
 surgical management, 197–8
- vulvodynia, 200
see also abdominal pain; endometriosis; pelvic pain
- clear cell cervical/vaginal cancer, 395–6
- clitoris, no eponym syndrome, 244
- cloaca abnormalities, 430
- colposcopes, 118
- combined contraceptive vaginal ring, 279–80
- combined oral contraceptives, 272–8, 301–2, 485
 abnormal vaginal bleeding, 206–7, 208–9
 adverse effects, 272–3, 301
 amenorrhea, 156
 breast cancer risk and, 263
 chronic pelvic pain, 196
 contraindications, 272–3, 275–6
 dual-method use, 278, 300
 dysmenorrhea, 173
 eligibility criteria, 276–7
 emergency contraception, 287–8
 endometrial effects, 463–4
 endometriosis, 183
 mechanism of action, 272
 menorrhagia, 213
 noncontraceptive benefits, 276
 PCOS, 331
 progestin and estrogen components, 273–5
- complete androgen insensitivity syndrome (CAIS), 21, 44–8
 clinical appearance, 44
 diagnosis, 47
 genetics, 46
 gonads and genital ducts, 44–5
 hormonal secretion, 45
 management, 47–8
 counseling, 47
 gender assignment, 47
 hormone replacement, 48
 surgical treatment, 48
 pathophysiology, 45–6
 psychosexual development, 46–7
see also androgen insensitivity (AIS)
- computed tomography (CT), 427
see also imaging
- condoms, 289–90, 300–1
 dual-method use, 278, 300
 efficacy, 290, 301
 female condom, 290–1, 302
 sexually transmitted infection prevention, 424–5
- condylomata acuminata, 73–5, 358
 treatment, 358–9
- confidentiality, 129, 455–6
see also consent issues
- congenital adrenal hyperplasia (CAH), 21, 25–33
 classic CAH, 28, 29–30
 clinical presentation, 28–9
 diagnosis, 25–8
 differential diagnosis, 25–6
 hormonal diagnosis, 26–7
 molecular genetics, 28, 29
 prenatal diagnosis, 31
 management, 23, 31–3
 during pregnancy, 32

- fetus, 31–2
 hormone replacement, 32–3
 nonclassic CAH, 28, 30–1
- consent issues, 453–5
 abortion, 455
 contraception, 455
 HIV/AIDS, 454–5
 sexually transmitted diseases, 454
- constipation, 343–4
- contact dermatitis, 363
- contraception, 138, 265–93, 299–305
 adolescent birth rates, 265–7
 choices, 269–92
 abstinence, 269–72
 combined hormonal systems, 278–80
 combined oral contraceptives, 272–8, 301–2
 condoms, 289–90, 300–1
 emergency contraception, 287–9, 302
 female condom, 290–1, 302
 implants and patches, 303
 intrauterine devices, 291–2, 303
 male hormonal contraception, 303
 progestin-only contraceptives, 280–7, 302, 303
see also individual methods
- consent issues, 455
 dual-method use, 268, 278, 300
 education, 5, 300
 eligibility criteria, 276–7
 failure rates, 268–9, 270
 increased usage, 267–8
 selected practice recommendations, 277–8
- contraceptive sponge, 291, 302–3
- copper IUDs, emergency contraception, 288
- corpus luteum cysts, 482–3
- counseling
 complete androgen insensitivity syndrome, 47
see also family counseling
- COX-2 inhibitors, chronic pelvic pain, 195–6
- critical pemphigoid, 375
- Cushing disease, 153
- cyclophosphamide, 152
- CYP21A2 gene mutations, 28, 29
- cystadenocarcinoma, 382
- cystadenoma, 382, 441
- cysts
 developmental, vulvar, 367–8
 Gartner duct, 429–30
 paraurethral, 12, 239, 365
see also ovarian cysts
- danazol, endometriosis, 183–4
- DDAVP, 212, 213
- delayed puberty *see* puberty
- Depo-Provera, 282–4
- depot medroxyprogesterone acetate (DMPA), 280, 282–4, 302
 adverse events, 283–4
 chronic pelvic pain, 197
 mechanism of action, 283
- noncontraceptive benefits, 284
- dermatitis *see* dermatologic disorders
- dermatologic disorders, 361–4, 369–79
 acrodermatitis enteropathica (AE), 372
 atopic dermatitis (AD), 6, 67–72, 370–1
 Behçet disease, 77–8, 360–1, 373–4
 benign familial pemphigus, 374
 bullous impetigo, 375
 chronic bullous disease of childhood (CBDC), 373
 contact dermatitis, 363
 critical pemphigoid, 375
 diaper dermatitis, 370
 genital warts, 73–5, 358–9
 hidradenitis suppurativa, 379
 labial agglutination, 6, 240–2, 364
 Langerhans cell histiocytosis (LHC), 371
 lichen planus, 73, 374–5
 lichen sclerosus, 72–3, 361–3, 372–3
 management, 369–70
 molluscum contagiosum, 75, 359, 377
 pediculosis pubis, 76, 378
 perineal streptococcal cellulitis, 375–6
 psoriasis, 76, 363–4, 371
 scabies, 76, 377–8
 seborrheic dermatitis, 371
 Turner syndrome, 39
- dermoid tumor, 381, 391
- desogestrel (DSG), 274
- dexametazone
 congenital adrenal hyperplasia, 31–2
 growth suppression, 32
- diaper dermatitis, 370
- disorders of sex development (DSD), 14–24, 36
 approach to family, 15
 classification, 20
 diagnosis, 19–20
 evaluation, 17–18
 incidence, 14
 investigations, 18–19
 management, 20–4
 gender assignment, 20–2
 hormone replacement, 23
 medical management, 23
 psychosocial management, 23–4
 surgical management, 22–3
 nomenclature, 20
 ovotesticular disorder of sex development, 42
see also congenital adrenal hyperplasia (CAH); gonadal dysgenesis
- documentation, sexual abuse, 121
 photodocumentation, 118
- drospirenone (DRSP), 274–5
- dysgerminoma, 388, 390–1, 439, 469–71
- dysmenorrhea, 171–3
 diagnosis, 172
 incidence, 171
 management, 172–3
 pathophysiology, 171–2
- ectopic kidney, 428–9
- ectopic pregnancy, 349–53
- ectopic ureter, 244
- education for life, 5–6
- embryo cryopreservation, 446–7
- embryonal carcinoma, 471
- emergency contraception (EC), 287–9, 302
 access to, 288–9
 combined emergency contraceptive pills (ECPs), 287–8
 copper IUDs, 288
 cost-effectiveness, 289
 progestin-only ECPs, 288
- endodermal sinus tumor (EST), 391, 471
- endometrial pathology, 462–5
 endometrial cancer, 446, 465
 hyperplasia, 462–3, 464, 465
 iatrogenic hormonal effects, 463–5
 hormonal antitumoral therapy, 465
 hormonal substitution therapy, 464–5
 oral contraceptives, 463–4
 ovulation stimulation therapy, 464
see also endometriosis
- endometrioma, 383
- endometriosis, 173, 177–89, 383, 433
 diagnosis, 178–82
 etiology, 177
 presentation, 178
 staging, 179–82
 treatment, 182–9
 aromatase inhibitors, 185
 danazol, 183–4
 GnRHa, 184
 hormonal suppression, 183
 NSAIDs, 183
 surgical treatment, 185–9, 251–2
- Enterobius vermicularis* (pinworms), 66, 378
- epithelial tumors, 382, 388, 394, 439–41, 446, 467–8
- estrogen replacement therapy
 androgen insensitivity, 48, 49
 disorders of sexual development, 23
 endometrial effects, 464
- estrogens
 androgen insensitivity syndrome, 45
 precocious puberty and, 166
see also combined oral contraceptives
- etonogestrel (ETN), 279, 285
- examination
 abnormal vaginal bleeding, 206, 211
 acute pelvic pain, 347–8
 adolescent, 58, 127
 first gynecologic examination, 127–8, 136–7
 child, 55–6
 dermatological conditions, 369
 newborn, 12–13
 sexual abuse, 115–18
see also specific conditions
- famciclovir, 410
- family counseling
 complete androgen insensitivity syndrome, 47

- family counseling (*Continue*)
 disorders of sex development and, 15
 fellowship development, 8
 female condom, 290–1, 302
 female genital mutilation (FGM), 105–6
 fertility preservation, 445, 446–8
 embryo cryopreservation, 446–7
 GnRH suppression, 448
 oocyte cryopreservation, 447
 oophorectomy, 447–8
 ovarian cryopreservation and transplantation, 447
 fetal therapy, congenital adrenal hyperplasia, 31–2
 fetus, 8
 PCOS origin, 326–7
 fibroadenoma, breast, 260, 261
 fibrocystic change, breast, 260
 fibroma, 394, 472
 9 α -fludrocortisone acetate, 33
 follicle-stimulating hormone (FSH), puberty, 159–60, 164
 follicular cysts, 7, 482
 folliculogenesis regulation, 324
 foreign bodies, vagina, 83, 104
 psychologic aspects, 131–2
 forensic evidence collection, 116
- galactorrhea, 262
 in newborns, 256–7
 Gartner duct cysts, 429–30
 gender assignment, 125
 androgen insensitivity, 47, 49
 disorders of sex development, 20–2
 gender identity
 complete androgen insensitivity syndrome, 46–7
 disorders of sexual development, 20–2
 genetic analysis, disorders of sex development, 19
 genetics
 complete androgen insensitivity syndrome, 46
 congenital adrenal hyperplasia, 28, 29
 PCOS, 323–5
 Turner syndrome, 37
see also genetic analysis
 genital herpes *see* herpes simplex virus (HSV)
 genital trauma, 97–109
 accidental penetrating vaginal injuries, 99–100
 age impact on genital tissues, 97–8
 bladder injuries, 103
 burns, 103–4
 coital vaginal injuries, 100–1
 crush injuries, 102
 female genital mutilation (FGM), 105–6
 management, 106–7
 motor vehicle accidents, 102
 psychologic factors, 108–9
 sexual abuse, 107–8
- straddle injuries, 99
 urethral injuries, 102–3
 vulvar hematomas, 99
- genital warts, 73–5, 358–9
see also human papillomavirus (HPV)
- germ cell tumors, 381, 388, 390–3, 468–71
 chemotherapy, 392–3
 imaging, 436–9
 mixed, 392
 presentation, 392
- gestational trophoblastic diseases, 474–9
 choriocarcinoma, 477–8
 complete hydatidiform mole, 475–6
 invasive mole, 477
 management, 478
 partial hydatidiform mole, 476–7
 placental site trophoblastic tumors, 478
- gestodene (GSD), 274
- glucocorticoid replacement, congenital adrenal hyperplasia, 32–3
- gonadal dysgenesis
 amenorrhea and, 151–2
 associated congenital anomalies, 42
 complete (CGD), 40
 etiology, 41
 embryonic testicular regression syndrome, 42
 gonadal tumor formation, 41
 ovotesticular disorder of sex development, 42
 partial (PGD), 40, 41–2
 Turner syndrome, 39
 46,XX (ovarian) gonadal dysgenesis, 42
 46,XY gonadal dysgenesis, 40–2
see also disorders of sex development (DSD)
- gonadarche, 160
 gonadoblastoma, 41, 391–2
 gonadotropin-releasing hormone agonist (GnRH_a)
 central precocious puberty, 167–8
 chronic pelvic pain, 197
 dysmenorrhea, 173
 endometriosis, 184
 leiomyoma, 465
- gonadotropin-releasing hormone (GnRH)
 ovarian suppression for fertility preservation, 448
 puberty and, 159–60, 163, 164
- gonorrhea, 353–5, 419–20
- granulosa cell tumors, 383, 388, 393, 472
- group A streptococcus, 65
 vaginal bleeding and, 82
- growth deficiency, Turner syndrome, 37–8
 growth hormone therapy, Turner syndrome, 40
- gynandroblastoma, 473
- Hailey–Hailey disease, 374
- health information privacy, 455–6
- hearing loss, Turner syndrome, 39
- hemangioma, vulvar, 365
 cavernous, 365–7
- hematoma
 cervical, 436
 vulvar, 99
- hepatitis B (HBV), 422
 vaccination, 425
- hermaphroditism, 42
see also disorders of sex development (DSD)
- herpes simplex virus (HSV), 359–60, 408–12, 420–1
 diagnosis, 409
 HSV-1, 408
 HSV-2, 75, 408
 in pregnancy, 410–12
 disseminated maternal herpetic infection, 411
 influence of infection, 411–12
 therapy, 412
 transmission to newborn, 411
 prevention of sexual transmission, 412
 primary infection, 408–9, 410–11
 recurrent infection, 409, 410–11
 therapy, 409–10, 412
 aciclovir (acyclovir), 409–10
 famciclovir, 410
 suppressive therapy, 410
 valaciclovir, 410
 vaccines, 426
- herpes zoster, 75
- hidradenitis suppurativa, 379
- histiocytosis X, 371
- history of pediatric and adolescent gynecology, 484–6
- history taking
 abnormal vaginal bleeding, 205–6, 210–11
 adolescent, 57–8, 135–6
 medical details, 126
 sexual history, 126, 136
- amenorrhea, 154
 family history, 154–5
- child, 55
 ovarian cysts, 383–4
 sexual abuse, 114–15
- HIV infection, 7, 422–3
 consent issues, 454–5
 education, 5–6
 testing recommendations, 424
- hormone therapy
 androgen insensitivity, 48, 49
 chronic pelvic pain, 196–7
 congenital adrenal hyperplasia, 32–3
 delayed puberty, 149
 disorders of sexual development, 23
 endometriosis, 183
 iatrogenic endometrial effects, 463–5
see also combined oral contraceptives
- human immunodeficiency virus *see* HIV infection
- human papillomavirus (HPV), 7, 397–400, 421–2, 457–61
 cervical cancer and, 457–61
 condylomata acuminata, 73–5, 358
 epidemiology, 398–9
 pathogenesis, 399
 subtypes, 458

- transmission, 399–400
treatment, 358–9
vaccination, 4–5, 403–6, 425–6, 460
vulvar infection, 358–9, 376–7
- hydatidiform mole, 474
complete, 474, 475–6
partial, 476–7
- hydrocolpos, 428
- hydrocortisone, congenital adrenal hyperplasia, 32–3
- hydrometrocolpos, 428
- 21-hydroxylase deficiency (21-OHD), 25, 27
pathophysiology, 25
see also congenital adrenal hyperplasia (CAH)
- 17-hydroxyprogesterone (17-OHP), 26–7
- hymen
imperforate, 13
no eponym syndrome, 235–7
microperforate, 13
no eponym syndrome, 237–8
partial septum, 245
polyps, 83
newborn, 13
no eponym syndrome, 239–40
sexual abuse and, 108
- hyperandrogenism
amenorrhea and, 153–4
PCOS, 318–19
anovulation, 320–1, 323
management, 330, 331–2, 334
prenatal androgenization, 326
- hypergonadotropic hypogonadism, amenorrhea and, 151–2
- hyperinsulinemia, anovulation and, 321–3
- hyperprolactinemia
amenorrhea and, 152
medications causing, 262
- hypogonadotropic hypogonadism, amenorrhea and, 152–3
- hypomastia, 258
- hypopituitarism, amenorrhea and, 152
- hypothalamus, amenorrhea and, 152–3
- hypothyroidism
precocious puberty, 166
Turner syndrome, 39
- imaging, 427–43
amenorrhea, 155–6
congenital abnormalities, 427–33
cloaca and allantois, 430
metanephric blastema and ureteral bud, 428–9
Müllerian duct, 427–8
processus vaginalis, 430–3
Wolffian duct, 429–30
normal variants, 427
pelvic neoplasms, 436–43
ovarian cysts, 384
pelvic pain, 433–6
imperforate hymen, 13
no eponym syndrome, 235–7
- Implanon[®], 280, 285–7
adverse events, 286
efficacy, 286
mechanism of action, 286
- infant, 9
- insulin
anovulation and, 321–3
genetic regulation of actions, 324–5
resistance, in PCOS, 327–30
management, 334–5
- International Federation of Infantile and Juvenile Gynecology, 487–91
- interstitial cystitis (IC), 199–200
- intestinal malrotation with volvulus, 343
- intrauterine devices (IUDs), 291–2, 303
adverse events, 292
copper, emergency contraception, 288
efficacy, 292
levonorgestrel-containing, chronic pelvic pain, 196–7
mechanism of action, 292
noncontraceptive benefits, 292
- intussusception, 342–3
- invasive mole, 477
- irritable bowel syndrome (IBS), 200
- juvenile granulosa cell tumors (JGCT), 472
- Klinefelter syndrome (47,XXY), 20
- labia minora agglutination, 6, 240–2, 364
- labium majus
abscess, 60–2
prepubertal unilateral fibrous hyperplasia, 242–4
- labor in adolescents, 311–14
- Langerhans cell histiocytosis (LHC), 371
- laparoscopy, 246–54
adnexal masses, 248–51
adnexal torsion, 356–7
anesthesia and pain management, 247–8
chronic pelvic pain, 175–7, 251–2
congenital anomalies, 252–4
ectopic pregnancy, 351–2
endometriosis, 185, 251
instrumentation, 246–7
peritoneal access, 247
peritoneal cavity inspection, 248
- leiomyoma, 465
vulvar, 367
- letrozole, endometriosis, 185
- leuprolide, endometriosis, 184
- levonorgestrel
emergency contraception, 287, 302
IUD (LNG-IUD), chronic pelvic pain, 196–7
- lichen planus, 73, 374–5
- lichen sclerosus, 72–3, 361–3, 372–3
treatment, 362–3, 372–3
- Lunelle, 280
- Lupron, 465
- luteinizing hormone (LH), puberty, 159–60, 164
- lymphatic system abnormalities, Turner syndrome, 39
- McCune-Albright syndrome, 85, 94, 165–6
- McIndoe procedure, 222–9
general surgical management, 223–4
graft-covered stent placement, 226–7
reasons for failure, 227–8
schedule of surgical events, 224
skin graft and stent preparation, 224–5
stent types, 227–8
vaginal space dissection, 225–6
- magnetic resonance imaging (MRI), 427
see also imaging
- male hormonal contraception, 303
- malrotation, intestinal, 343
- mastalgia, 260
- mastitis, 259
- masturbation, 128
- Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome *see* Rokitansky syndrome
- Meckel's diverticulum, 344
- medical testimony, child protection cases, 449–52
- menarche, 160
premature, 85
- meningomyelocele, 78
- menorrhagia, 210
treatment, 213
see also abnormal vaginal bleeding
- mental health management *see* psychosocial management
- metabolic syndrome (MetS), 333, 334
risk subphenotypes, 334
- metformin, 334–5
- methotrexate, ectopic pregnancy, 352–3
- microbicides, 426
- microperforate hymen, 13
no eponym syndrome, 237–8
- minor's rights, 453
consent issues, 453–5
abortion, 455
contraception, 455
HIV/AIDS, 454–5
sexually transmitted diseases, 454
health information privacy, 455–6
- mittelschmerz, 344
- mixed gonadal dysgenesis (MGD), 22
- molluscum contagiosum, 75, 359, 377
- mosaicism, 19
45,X0/46,XY mosaicism, 40
Turner syndrome, 37
- mucous cyst, vulvar, 367
- Müllerian aplasia, 151
- Müllerian duct abnormalities, 427–8
- Müllerian inhibiting factor (MIF)
androgen insensitivity syndrome, 45

- narcotics, chronic pelvic pain, 196
Neisseria gonorrhoeae, 353–5, 419–20
 neonate *see* newborn
 neurologic abnormalities, Turner syndrome, 39–40
 newborn, 8–9
 evaluation, 12–13
 nipples
 congenital anomalies, 258
 discharge, 262
 bloody, in neonates and infants, 257
 evaluation, 262–3
 inverted, 244–5, 258
 piercing, 263
see also breast
 no eponym syndrome, 231–45
 complete transverse vaginal septum, 238–9
 differential diagnosis, 240–2
 distal longitudinal vaginal mucosal folds, 242
 ectopic ureter, 244
 imperforate hymen, 235–7
 inverted nipples, 244–5
 large clitoris, 244
 longitudinal vaginal septum, 234–5
 microperforate hymen, 237–8
 paraurethral cyst, 239
 partial hymen septum, 245
 polyps of the hymen, 239–40
 prepubertal unilateral fibrous hyperplasia of the labium majus, 252–5
 presentation, 231–2
 surgical treatment, 232–4
 nonsteroidal anti-inflammatory drugs (NSAIDs)
 chronic pelvic pain, 195
 dysmenorrhea, 172–3
 endometriosis, 183
 norgestromin (NGMN), 278
 norgestimate, 274
 Norplant[®], 280, 284–5
 adverse events, 285
 efficacy, 285
 mechanism of action, 284–5
 North American Society of Pediatric and Adolescent Gynecology, 485–6
 NuvaRing[®], 280
 obesity, PCOS and, 319
 anovulation, 321
 management, 333–4
 obstetric management, 314–15
 oocyte cryopreservation, 447
 oophorectomy, 447–8
 oral contraceptives *see* combined oral contraceptives;
 progestin-only contraceptives
 ovulation stimulation therapy, 464
 ovarian cryopreservation and transplantation, 447
 ovarian cysts, 7–8, 248
 adolescent and young adult, 380–8
 complex adnexal mass, 386–8
 epidemiology, 380–1
 evaluation, 383–5
 management, 385–8
 pathologic cysts, 381–3
 childhood, 92–5
 diagnosis, 92–3
 management, 93–5
 presentation, 92
 surgical techniques, 94–5
 complex ovarian cyst, 7–8
 corpus luteum cysts, 482–3
 fetal, 87–90
 delivery recommendations, 90
 diagnosis, 87–8
 etiology, 87
 management, 89–90
 natural history, 88–9
 follicular cysts, 7, 482
 hemorrhagic, 434
 infancy, 90–2
 management, 90–2
 presentation, 90
 precocious puberty and, 166
see also adnexal torsion; polycystic ovarian syndrome (PCOS)
 ovarian function, cancer treatment effects, 445
 acute ovarian failure (AOF), 445
 premature ovarian failure (POF), 445
see also fertility preservation
 ovarian torsion *see* adnexal torsion
 ovarian tumors, 1, 92, 382, 387–8, 390–5, 467–73
 borderline tumors, 394–5, 446, 468
 classification, 467
 epithelial tumors, 382, 388, 394, 439–41, 446, 467–8
 germ cell tumors, 381, 388, 390–3, 436–9, 468–71
 imaging, 436–41
 stromal tumors, 383, 388, 393–4, 441
see also ovarian cysts; *specific tumors*
 Pap testing *see* cervical cytology
 paraurethral cyst, 12, 239, 365
 partial androgen insensitivity syndrome (PAIS), 21, 48–9
 clinical appearance, 48
 diagnosis, 48–9
 hormones, 48
 management, 48–9
 gender assignment, 49
 hormone replacement, 49
 psychologic treatment, 49
 surgical treatment, 49
 pathophysiology, 48
see also androgen insensitivity (AIS)
 patent anus, 13
 pediculosis pubis, 76, 378
 pelvic changes in puberty, 309–10
 pelvic inflammatory disease (PID), 65, 353–6
 evaluation, 354–5
 sexually transmitted infections and, 419–20
 treatment, 355–6
 pelvic pain, 8
 imaging, 433–6
see also abdominal pain; acute pelvic pain;
 chronic pelvic pain (CPP)
 penile agenesis, 22
 perineal granuloma, 240
 perineal streptococcal cellulitis, 375–6
 peritonitis, 341, 342, 346
 Peutz-Jeghers syndrome, 473
 phylloides tumor, 260, 261
 physical therapy, chronic pelvic pain, 199
 pinworms, 66, 378
 pituitary function, amenorrhea and, 152
 polycystic ovarian syndrome (PCOS), 8, 316–36, 483
 amenorrhea and, 153–6
 challenges, 316
 definition, 317–18
 diagnosis, 318–19
 differential diagnosis, 319–20
 management, 156, 330–6
 endometrial dysfunction, 332
 hyperandrogenemia, 330, 331–2
 lifestyle interventions, 335–6
 metabolic derangements, 332–6
 opportunities, 317
 pathophysiology, 320–30
 anovulation, 320–3
 developmental origin, 325–7
 genetic basis, 323–5
 insulin resistance and, 327–30
 polymastia, 258
 polyps
 endometrial, 173
 hymen, 83
 newborn, 13
 no eponym syndrome, 239–40
 polythelia, 258
 precocious puberty *see* puberty
 prednisolone
 growth suppression, 32
 pregnancy, 138–9
 congenital adrenal hyperplasia management, 32
 early pregnancy complications, 348–53
 ectopic, 349–53
 herpes infection, 410–12
 disseminated maternal herpetic infection, 411
 influence of infection, 411–12
 therapy, 412
 transmission to newborn, 411
 labor in adolescents, 311–14
 obstetric management, 314–15
 unwanted, 1, 485
 premature menarche, 85
 premature ovarian failure (POF), 445, 464
 premature pubarche, PCOS, 319
 premature thelarche, 6–7, 161–2, 257–8
 prenatal androgenization, PCOS, 326
 prenatal diagnosis

- congenital adrenal hyperplasia, 31
- ovarian cysts, 87–8
- prenatal therapy
 - congenital adrenal hyperplasia, 31–2
 - ovarian cysts, 89–90
- prepubertal child, 9–10
- primary ovarian insufficiency (POF), 151, 152
- processus vaginalis, 430–3
- progesterone
 - endometrial carcinoma treatment, 465
 - endometrial effects, 463, 465
- progestin-only contraceptives, 280–7
 - Depo-Provera, 282–4
 - implants and patches, 303
 - Implanon[®], 285–7
 - Norplant[®], 284–5
 - progestin-only pills (POPs), 280, 281
 - emergency contraceptive pills, 288, 302
- prolapse, urethral, 83–4, 364–5
 - treatment, 365
- psoriasis, 76, 363–4, 371
- psychosocial management
 - androgen insensitivity, 49
 - chronic pelvic pain, 198–9
 - disorders of sexual development, 23–4
 - Rokitansky syndrome, 133
 - Rokitansky syndrome, 218–19
 - sexual abuse and, 120–1
- puberty, 10, 141–4, 145–7, 159–61
 - age of, 159
 - central nervous system changes, 161
 - delayed, 145–9
 - causes, 148
 - differential diagnosis, 145
 - genetic disorders, 149
 - laboratory evaluation, 148–9
 - therapy, 149
 - early, 161–2
 - genetic/molecular control of, 160
 - hormonal changes, 160
 - physical changes, 160, 161
 - pelvic changes, 309–10
 - physiology of, 159–60
 - precocious, 6–7, 162–8, 258
 - category differentiation, 163
 - central precocious puberty (CPP), 153, 165, 166–8
 - diagnosis, 162–3, 164–5
 - GnRH-independent precocious puberty, 163, 165–6
 - PCOS and, 319
 - physical findings, 164
 - treatment of underlying abnormalities, 166–8
 - terminology, 160
 - see also* adolescent
 - pubic hair development, 142
 - premature, PCOS, 319
 - pyelonephritis, 436
- radiation therapy, amenorrhea and, 152
- renal abnormalities, Turner syndrome, 38
- renal abscess, 436
- renal calculi, 435–6
- reproductive performance, immature
 - mammals, 308–9
- rhabdomyosarcoma, 1, 7, 84–5, 245, 395, 442, 480–1
 - evolution, 481
 - histopathology, 480–1
 - presentation, 480
- Rokitansky syndrome, 13, 132, 215–29, 253, 428
 - diagnosis, 215–18
 - differential diagnosis, 217–18
 - management, 218–29
 - menstruating uterus without a vagina, 221–2
 - surgical treatment, 219–21, 222–9, 253–4
 - vaginal dilation, 219
 - see also* McIndoe procedure
 - salpingitis, 65
 - salt-wasting (SW), 25, 26, 33
 - scabies, 76, 377–8
 - Schiller–Duval bodies, 391
 - sclerosing stromal tumors, 472
 - screening
 - breast screening, 263
 - cervical cancer, 401–2
 - see also* cervical cytology
 - sexually transmitted infections, 423–4
 - seborrheic dermatitis, 371
 - selective serotonin reuptake inhibitors (SSRIs),
 - chronic pelvic pain, 198
 - Sertoli cell tumors, 472
 - Sertoli–Leydig cell tumors, 383, 393–4, 473
 - sex assignment *see* gender assignment
 - sex cord stromal tumors, 383, 388, 393–4, 441, 471–3
 - sex cord tumors with annular tubules (SCAT), 394, 473
 - sex determination, 36
 - sexual abuse, 107–8, 111–22
 - child protection issues, 449–52
 - definitions, 111–12
 - documentation, 121
 - photodocumentation, 118
 - evaluation, 113–18
 - behavioral symptoms, 115
 - examination, 115–18
 - forensic evidence collection, 116
 - history, 114–15
 - physical symptoms, 115
 - sexually transmitted infections, 118, 119
 - management, 118–22
 - mental health, 120–1
 - physician role in investigation, 121
 - physician role in testimony, 122
 - presentations, 112–13
 - prevention strategies, 122
 - sexually transmitted infections and, 118, 119, 432
 - sexual development, 15–17
 - nomenclature, 16
 - see also* disorders of sex development (DSD)
 - sexual differentiation, 16, 36
 - sexuality, 124–30, 485
 - embryology of, 124
 - female and male sexual anlagen, 124–5
 - forms of, 125
 - mass media role, 300
 - physiology of, 125
 - sexually transmitted infections (STIs), 7, 65, 300, 415, 416
 - adolescents, 129, 137–8
 - burden of, 415–16
 - consent issues, 454
 - costs of, 354
 - diseases characterized by cervicitis and PID, 419–20
 - diseases characterized by genital ulceration, 420–2
 - diseases characterized by vaginal discharge, 418–19
 - education, 5–6
 - pelvic inflammatory disease and, 353–5
 - prevention, 423–6
 - recognition of, 416–17
 - sexual abuse and, 112, 423
 - testing for, 118, 119
 - treatment considerations, 423
 - see also specific infections*
 - skeletal abnormalities, Turner syndrome, 38
 - speculum, 55, 58
 - stature, Turner syndrome, 37–8
 - steroid replacement *see* hormone therapy
 - steroid-responsive elements (SRE), 43, 44
 - steroidogenesis, 26
 - see also* congenital adrenal hyperplasia (CAH)
 - straddle injuries, 99
 - streptococcal cellulitis, 375–6
 - stromal tumors, 383, 388, 393–4, 441, 471–3
 - suicide, 2
 - syphilis, 421
 - tamoxifen, 465
 - Tanner scale, 127, 141–2, 484
 - teratoma, 92, 93–4, 249–50, 381, 437–8, 468–9
 - benign cystic, 381, 386–7
 - immature, 391, 438, 469
 - testosterone, 43
 - androgen insensitivity syndrome, 45
 - anovulation and, 320–1
 - sex differentiation and, 36
 - testosterone estradiol-binding globulin (TEBG), 45
 - testosterone replacement therapy
 - disorders of sexual development, 23
 - theca cell tumors, 383
 - thecoma, 394
 - thelarche, 160, 257
 - premature, 6–7, 161–2, 257–8
 - thyroid abnormalities, Turner syndrome, 39
 - thyroxine-binding globulin, 45

- tinea cruris, 76
transcutaneous electrical nerve stimulation (TENS), chronic
pelvic pain, 199
transdermal contraceptive patch, 278–9
 drug interactions, 279
Treponema pallidum, 521
trichomoniasis, 418–19
tricyclic antidepressants (TCAs), chronic pelvic pain, 198
trophoblast, 474
trophoblastic diseases *see* gestational trophoblastic diseases
tuberous breast deformity, 258
tubo-ovarian abscess (TOA), 353, 354, 355, 434–5
tumor markers, 384–5
Turner syndrome (45,X0), 20, 36–40
 clinical presentation, 37–40
 etiology, 40
 genetics, 37
 history, 36–7
 management, 40
- ulcerations
 sexually transmitted infections and, 420–2
 vulvar, 359–61
 aphthous ulceration, 360–1
 Behçet disease, 77–8, 360–1, 373–4
ultrasound, 427
 see also imaging
ureter, ectopic, 244
urethra
 newborn evaluation, 12
 prolapse, 83–4, 364–5
 treatment, 365
 trauma, 102–3
urinary tract infection, 6
urogenital sinus, 238
uterine congenital abnormalities, 427–9
 see also no eponym syndrome; Rokitansky syndrome
- vaccination
 genital herpes, 426
 hepatitis B, 425
 human papillomavirus, 4–5, 403–6, 425–6, 460
vagina
 congenital abnormalities, 427–8
 see also no eponym syndrome; Rokitansky syndrome
 foreign bodies, 83, 104
 psychologic aspects, 131–2
 newborn evaluation, 12–13
 penetrating injuries, 99–101
 accidental, 99–100
 coital injury, 100–1
 xanthogranuloma, 85
 see also genital trauma
 vaginal bleeding *see* abnormal vaginal bleeding
 vaginal dilation, 219
 vaginal discharge
 child, 63–4
 physiologic discharge, 64
 sexually transmitted diseases and, 418–19
 vaginal septum, 428
 complete transverse, 238–9
 longitudinal, 234–5
 vaginal sponge, 291, 302–3
 vaginitis, 6, 418
 candida, 65–6
 see also vulvovaginitis
 vaginotomy indications, 64–5
 valaciclovir, 410
 volvulus, 343
 von Willebrand disease (vWD), 84, 210, 212
 vulva disorders
 bleeding, 83
 congenital venous malformation, 365–7
 dermatologic conditions *see* dermatologic disorders
 developmental cysts, 367–8
 hemangioma, 365
 cavernous, 365–7
 hematomas, 99
 infectious disorders, 358–9
 candidiasis, 358
 HPV, 358–9
 molluscum contagiosum, 359
 leiomyoma, 367
 ulcerations, 359–61
 urethral disorders, 364–5
 see also genital trauma; vulvovaginitis
 vulvitis, 6, 63
 primary, 60
 see also vulvovaginitis
 vulvodynia, 78, 200
 vulvovaginitis, 60–80
 acute deep unilateral labium major abscess, 60–2
 causes, 62, 65–78
 clinical judgement, 64
 culture interpretation, 65
 management, 79–80
 psychologic aspects, 131
 susceptibility of child, 60
 vaginal discharge, 63–4
 vaginotomy indications, 64–5
 see also dermatologic disorders; vagina; vulva disorders
- warts, genital, 73–5, 358–9
 see also human papillomavirus (HPV)
Wolffian duct abnormalities, 429–30
- X haploinsufficiency, 40
 see also Turner syndrome (45,X0)
xanthogranuloma of the vagina, 85
45,X0 *see* Turner syndrome
45,X0/46,XY mosaicism, 40
45,X/46,XY (MGD), 20
46,XX gonadal dysgenesis, 42
46,XX/46,XY (MGD), 20
47,XXY (Klinefelter syndrome) *see* Klinefelter syndrome
46,XY gonadal dysgenesis, 40–2
yolk sac tumor, 391, 471
young adult, 10, 58–9
young child, 9